All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

VTP-200 Elicits Immunogenic Responses, Tolerability in HPV+ Cervical Lesions

March 20th 2023

VTP-200 generated immunogenic responses and tolerability in patients with human papillomavirus–positive cervical lesions.

Allocetra Plus Chemotherapy Receives Green Light to Continue Investigation in Solid Tumors With Peritoneal Metastasis

March 20th 2023

The phase 1/2 trial evaluating the addition of Allocetra to standard chemotherapy administered via pressurized intraperitoneal aerosol chemotherapy received regulatory clearance to continue evaluation and launch the dose-escalation cohort in patients with advanced-stage peritoneal metastasis arising from solid tumors following the completion of an interim data review by an Independent Data and Safety Monitoring Board and the Israeli Ministry of Health.

Dostarlimab Fills Unmet Need for Patients with dMMR Advanced Endometrial Cancer

March 20th 2023

Lucy Gilbert, MD, MSc, discusses the favorable safety profile of dostarlimab as well as how it compares with the current standard of care in mismatch repair deficient advanced endometrial cancer.

Patritumab Deruxtecan Continues to Generate Responses in Previously Treated EGFR-Mutated NSCLC and HER3-Expressing Breast Cancer

March 20th 2023

Patritumab deruxtecan elicited responses in previously treated patients with EGFR-mutated metastatic or unresectable non–small cell lung cancer and patients with HER3-expressing metastatic breast cancer.

First-line ASCT Consolidation Confers Real-world Survival Benefit in Mantle Cell Lymphoma

March 20th 2023

Consolidative autologous stem cell transplant was associated with a statistically significant lower overall mortality risk and higher overall survival probability in patients with mantle cell lymphoma vs those who did not receive consolidation.

Cancer Center Leader Appointed to Establish Inaugural Office

March 20th 2023

Jennifer Hatcher, PhD, RN, MPH, has been appointed as associate director of Inclusivity, Diversity, Equity and Accessibility for the University of Arizona Cancer Center.

Integrating New Standards for Metastatic HER2+ Breast Cancer

March 20th 2023

The first-line standard of care for patients with HER2-postive metastatic breast cancer has long been held by the combination of pertuzumab, trastuzumab, and a taxane established with the publication of data from the CLEOPATRA trial.

Immunotherapy and Targeted Therapies Continue to Improve Patient Outcomes in Lung Cancer

March 20th 2023

Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.

ASCT Following First Complete Remission Does Not Improve Real-World Survival in Mantle Cell Lymphoma

March 19th 2023

First-line consolidative autologous stem cell transplant following first complete remission, with or without maintenance rituximab, did not result in improved overall survival for patients with mantle cell lymphoma.

Triplets and Targeted Therapies May Strengthen the R/R AML Armamentarium

March 18th 2023

Eunice Wang, MD, discusses the current standards for classifying and treating unfit patients with AML, treatment considerations for patients unfit for hypomethylating agents, and the potential role of investigational menin inhibitors and immunotherapies in this population.

JTX-8064 Plus Pimivalimab Elicits Durable Responses in Platinum-Resistant Ovarian Cancer

March 17th 2023

The combination of JTX-8064 and pimivalimab generated deep and durable responses in patients with third- or fourth-line platinum-resistant ovarian cancer.

Maintenance Avelumab Plus Lurbinectedin Under Investigation in Metastatic Urothelial Carcinoma

March 17th 2023

Investigators are assessing the combination of avelumab and lurbinectedin as maintenance therapy for patients with metastatic urothelial carcinoma who achieve a response or stable disease following first-line, platinum-based chemotherapy in a single-arm phase 2 trial.

PARP7 Inhibitor RBN-2397 Has Tolerable Safety Profile in Solid Tumors

March 17th 2023

RBN-2397, a PARP7 inhibitor, was found to be well tolerated and have preliminary antitumor activity as monotherapy in patients with advanced solid tumors, including head and neck squamous cell carcinoma, breast cancer, and squamous cell carcinoma of the lung.

DNA Methylation Makes Cancer Cells More Vulnerable to Immune Response, Fox Chase Cancer Center Study Shows

March 17th 2023

A new study by Fox Chase Cancer Center scientists shows how DNA methylation can regulate the immune response in colorectal cancer, laying the groundwork for potential new treatments. .

Vibostolimab/Pembrolizumab Coformulation Fails to Reach PFS End Point in Pretreated Metastatic NSCLC

March 17th 2023

A coformulation of pembrolizumab and vibostolimab did not elicit a statistically significant improvement in progression-free survival vs docetaxel in pretreated patients with metastatic non–small cell lung cancer.

Enzalutamide Plus Leuprolide Improves MFS in Nonmetastatic Castration-Sensitive Prostate Cancer

March 17th 2023

Enzalutamide plus leuprolide demonstrated a statistically significant and clinically meaningful improvement in metastasis-free survival compared with placebo plus leuprolide in patients with nonmetastatic castration-sensitive prostate cancer with a high-risk of biochemical recurrence.

Coleman Illuminates Opportunities in Gynecologic Malignancies

March 17th 2023

Robert L. Coleman, MD, FACOG, FACS, the 2020 Giants of Cancer Care® award winner in gynecologic malignancies, notes that despite the great progress in the past decade, more work is needed to personalize and refine approaches to care.

Pembrolizumab Data Highlight Potential for Adjuvant Immunotherapy in RCC

March 17th 2023

Christopher W. Ryan, MD, discusses the role of adjuvant pembrolizumab in renal cell carcinoma, the use of immunotherapy-based combinations in the frontline setting for metastatic renal cell carcinoma, and key data presented at the 2023 Genitourinary Cancers Symposium in bladder cancer and prostate cancer.

FDA Approves Dabrafenib Plus Trametinib for Pediatric Patients With BRAF V600E–Mutated Low-Grade Glioma

March 16th 2023

The FDA has approved dabrafenib with trametinib for the treatment of pediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy.

CaboPoint Data Underscore Potential for Cabozantinib Following Frontline Combination Therapy in Advanced RCC

March 16th 2023

Laurence Albigès, MD, PhD, discusses what inspired the launch of the CaboPoint study examining second-line cabozantinib in patients with advanced renal cell carcinoma, the efficacy of this approach, and the next steps for this research.